<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524235</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2017-03-Merin-HaploBFR</org_study_id>
    <nct_id>NCT03524235</nct_id>
  </id_info>
  <brief_title>Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL</brief_title>
  <official_title>IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noah Merin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Miltenyi Biomedicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to examine the investigational use of the conditioning regimen&#xD;
      (bendamustine, fludarabine, and rituximab) prior to haploidentical peripheral blood&#xD;
      allogeneic stem cell transplantation with Post-Transplant Cyclophosphamide. The study will&#xD;
      also test the investigational use of CD56-enriched Donor Lymphocyte Infusion to see if this&#xD;
      treatment is safe, and whether or not it will help patients achieve better outcomes&#xD;
      post-transplant, including reduced risk of Graft-Versus-Host Disease (GVHD), and preventing&#xD;
      disease relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center Phase I trial of a new haploidentical stem cell transplant regimen&#xD;
      intended to assess safety. Two groups of patients are planned: patients with lymphoma and&#xD;
      patients with multiple myeloma. Each subject will receive a haploidentical stem cell&#xD;
      transplantation using peripheral blood stem cells. Bendamustine-fludarabine-rituximab-TBI&#xD;
      conditioning will be used, followed by stem cell infusion, with Post-Transplant&#xD;
      Cyclophosphamide and tacrolimus for GVHD prophylaxis. Patients will receive a CD56-selected&#xD;
      DLI on day +8. Evaluations will be taken at baseline and at each of the study visits.&#xD;
      Screening data will be reviewed to determine subject eligibility. Subjects who meet all&#xD;
      inclusion criteria and none of the exclusion criteria will be entered into the study. Total&#xD;
      duration of subject participation will be one year. Total duration of the study is expected&#xD;
      to be three years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Survival at 30 days post -transplantation</measure>
    <time_frame>30 Days</time_frame>
    <description>Proportion of patients undergoing BFR-TBI conditioning + haploidentical alloHSCT alive at 30 days post-transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of neutrophil engraftment at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of patients undergoing BFR-TBI conditioning + haploidentical alloHSCT with neutrophil engraftment at 30 days post-transplantation.&#xD;
-Neutrophil engraftment is defined as ANC recovery to &gt;500/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of platelet recovery at 100 days post-transplantation</measure>
    <time_frame>100 days</time_frame>
    <description>Proportion of patients with platelets &gt; 20/uL with no platelet transfusions within the prior 7 days at day 100 post-transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe chronic GVHD at 365 days post-transplantation</measure>
    <time_frame>365 days</time_frame>
    <description>Proportion of patients with severe chronic GVHD at day 365 post-transplantation.&#xD;
-Severe chronic GVHD is defined by NIH Consensus Criteria for GVHD severity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>CLL</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-Transplantation Conditioning (Bendamustine, Fludarabine, and Rituximab + Total Body Irradiation) + Haploidentical Stem Cell Transplantation with CD56-enriched donor lymphocyte infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>Pre-Transplantation Total Body Irradiation</description>
    <arm_group_label>Subjects</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Haploidentical Stem Cell Transplantation</intervention_name>
    <description>Haploidentical Stem Cell Transplantation</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD56-Enriched Donor Lymphocyte Infusion</intervention_name>
    <description>CD56-Enriched Donor Lymphocyte Infusion</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Pre-Transplantation Bendamustine</description>
    <arm_group_label>Subjects</arm_group_label>
    <other_name>Bendeka; Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Pre-Transplantation Fludarabine</description>
    <arm_group_label>Subjects</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)</description>
    <arm_group_label>Subjects</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria (For Treatment Groups)&#xD;
&#xD;
          -  Patient age 18 - 75 years&#xD;
&#xD;
          -  ECOG 0 - 2&#xD;
&#xD;
          -  HIV-positive patients are allowed if these criteria are met:&#xD;
&#xD;
               1. No history of opportunistic infections&#xD;
&#xD;
               2. CD4+ cell count greater or equal to 250 cells/mm3&#xD;
&#xD;
               3. No history of non-malignancy AIDS-defining conditions other than historical low&#xD;
                  CD4+ cell counts&#xD;
&#xD;
               4. Patient is on antiretroviral therapy with undetectable viral load. There must be&#xD;
                  minimal interactions of the antiviral therapy with the experimental treatment&#xD;
                  (antiretroviral such as ritonavir is potent CYP3A4 inhibitor and p-gp inducer may&#xD;
                  interact with tacrolimus resulted in increased serum concentration of&#xD;
                  tacrolimus).&#xD;
&#xD;
          -  Patients must have a related donor or who is at minimum HLA haploidentical. The donor&#xD;
             and recipient must be identical at least one allele of each of the following genetic&#xD;
             loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. A minimum match of 5/10 is&#xD;
             therefore required, and will be considered sufficient evidence that the donor and&#xD;
             recipient share one HLA haplotype. An unrelated donor search is not required.&#xD;
             (Patients with a readily-available, suitable, fully-matched sibling donor less than&#xD;
             age 55 are not eligible for this trial, these patients should proceed to transplant&#xD;
             using the matched related donor as standard-of-care).&#xD;
&#xD;
        Criteria for Donor Eligibility&#xD;
&#xD;
          -  Age greater than 12 years&#xD;
&#xD;
          -  Donors must meet the selection criteria as defined by the Foundation for the&#xD;
             Accreditation of Hematopoietic Cell Therapy (FACT).&#xD;
&#xD;
          -  In the event that two or more eligible donors are identified, the following order of&#xD;
             priority will be used to determine the preferred donor:&#xD;
&#xD;
               -  Medically and psychologically fit and willing to donate&#xD;
&#xD;
               -  For CMV seronegative recipients, a CMV seronegative donor&#xD;
&#xD;
               -  Red blood-cell compatibility&#xD;
&#xD;
                    -  RBC cross-match compatible&#xD;
&#xD;
                    -  Minor ABO incompatibility&#xD;
&#xD;
                    -  Major ABO incompatibility&#xD;
&#xD;
          -  If more than one preferred donor is identified and there is no medical, HLA- or KIR&#xD;
             ligand reason to prefer one of them, then the following guidelines are recommended:&#xD;
&#xD;
        If the patient is male, choose a male donor:&#xD;
&#xD;
          -  Choose the youngest preferred donor&#xD;
&#xD;
          -  If the patient and family express a strong preference for a particular donor, use that&#xD;
             one.&#xD;
&#xD;
        Inclusion Criteria (Lymphoma)&#xD;
&#xD;
          -  Diagnosis of resistant or relapsed CLL, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, T-cell&#xD;
             lymphoma, NK or NK/T Lymphoma.&#xD;
&#xD;
          -  Meets one of the following criteria:&#xD;
&#xD;
               -  relapsed after auto-transplant, or&#xD;
&#xD;
               -  failed to mobilize autologous stem cells, or&#xD;
&#xD;
               -  for whom allogeneic stem cell transplant is deemed appropriate given disease risk&#xD;
                  factors that make cure with autologous transplant seem unlikely, such as history&#xD;
                  of chemotherapy refractoriness, high risk disease&#xD;
                  features/mutations/translocations (e.g., Double Hit / Double Expressor DLBCL),&#xD;
                  short remission after prior chemotherapy, or histologic transformation (see&#xD;
                  below).&#xD;
&#xD;
          -  For Patients with Aggressive Mantle Cell and Diffuse Large B Cell Lymphoma who have&#xD;
             not had a prior autologous transplant:&#xD;
&#xD;
               -  Must have received at least 2 lines of prior therapy, and&#xD;
&#xD;
               -  Have been exposed to anthracycline, and&#xD;
&#xD;
               -  High and High-Intermediate aaIPI score (2 or 3 factors), and&#xD;
&#xD;
               -  Have relapsed within one year of primary therapy&#xD;
&#xD;
          -  For diagnosis of other aggressive lymphoma (e.g. NK/T Lymphoma, T Cell&#xD;
&#xD;
        Lymphoma, etc.):&#xD;
&#xD;
          -  Must have received at least 2 lines of prior therapy, and&#xD;
&#xD;
          -  Relapsed within 12 months of most recent therapy&#xD;
&#xD;
               -  For low-grade lymphomas / CLL:&#xD;
&#xD;
               -  Standard risk patients (absence of del(17p), absence of del(11q), no TP53&#xD;
                  mutation and absence of complex karyotype) must have progressed on BCR inhibitor,&#xD;
                  or undergone histologic transformation, to be eligible.&#xD;
&#xD;
               -  Patients with high risk disease (del(17p) or TP53 mutations and/or complex&#xD;
                  phenotype) who relapse after frontline therapy, demonstrate refractory disease to&#xD;
                  second line therapy (not BCR inhibitors), but show an objective response to BCR&#xD;
                  inhibitors are eligible to be taken off BCR inhibitors in order to proceed to&#xD;
                  alloHSCT on trial. Patients with high risk disease who relapse after frontline&#xD;
                  therapy, demonstrate refractory disease to second line therapy including BCR&#xD;
                  inhibitors (not BCL-2 inhibitors), but show an objective response to BCL-2&#xD;
                  inhibitors (venetoclax) are eligible to be taken off BCL-2 inhibitors in order to&#xD;
                  proceed to alloHSCT on trial.&#xD;
&#xD;
               -  For aggressive lymphomas, partial or complete remission (PR or CR) is required&#xD;
                  prior to alloHSCT.&#xD;
&#xD;
               -  Regarding CD20 expression: Patients with B cell malignancies that were CD20+ at&#xD;
                  any level at the time of relapse diagnosis (including partial / dim staining on&#xD;
                  IHC or partial / low level expression by flow cytometry) will receive rituximab&#xD;
                  as part of allogeneic transplant conditioning, if indicated. Patients with&#xD;
                  primary-refractory disease who were CD20+ at any level at the time of diagnosis&#xD;
                  will likewise receive rituximab, if indicated. Patients with histologies that&#xD;
                  were CD20- will not receive rituximab (T cell lymphoma, NK/T lymphoma, etc.).&#xD;
                  Fresh tissue / repeat biopsy is not required; the most recent biopsy will be&#xD;
                  reviewed to assess CD20 status.&#xD;
&#xD;
        Inclusion Criteria (Multiple Myeloma)&#xD;
&#xD;
        - Patient age 18 - 75 years with:&#xD;
&#xD;
          -  Early relapse (less than 24 months) after primary therapy that included an autologous&#xD;
             HSCT, or&#xD;
&#xD;
          -  High risk multiple myeloma defined as t(4;14), del(17p), -13, t(14;16), amp (1q21),&#xD;
             chromosome 8q24.1/c-MYC abnormality, or LDH &gt; ULN at diagnosis, provided patients&#xD;
             respond favorably to salvage therapy before enrollment for alloHSCT on trial and&#xD;
             patient is age &lt; 55, or&#xD;
&#xD;
          -  Patients failing to mobilize peripheral blood stem cells for autologous&#xD;
             transplantation, or&#xD;
&#xD;
          -  Extramedullary disease at diagnosis or relapse, or&#xD;
&#xD;
          -  Plasma-cell leukemia with chemosensitive disease&#xD;
&#xD;
        Inclusion Criteria - Control Patients (specimen collection, only)&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell&#xD;
             transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD&#xD;
             prophylaxis.&#xD;
&#xD;
          -  Willing to provide longitudinal blood samples per Control Specimen Collection Calendar&#xD;
             for correlative studies (for comparison to specimens from patients treated on the&#xD;
             trial).&#xD;
&#xD;
          -  Agrees to let study personnel collect excess bone marrow aspirate whenever a bone&#xD;
             marrow biopsy is performed for clinical purposes, and use for research.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patient has a readily-available, suitable, fully-matched sibling donor (MRD) less than&#xD;
             age 55. 'Suitable' means no high-titre donor-specific antibodies present, and negative&#xD;
             IDM testing with no contraindications.&#xD;
&#xD;
          -  Patient has a clinically-significant donor-specific antibody for the selected donor&#xD;
             (DSA clearance is not allowed).&#xD;
&#xD;
          -  Poor cardiac function: left ventricular ejection fraction &lt;45% as determined by MUGA&#xD;
             or ECHO.&#xD;
&#xD;
          -  Symptomatic pulmonary disease. Poor pulmonary function: FEV1, FVC, and DLCO &lt;50%&#xD;
             predicted (corrected for hemoglobin) for patients who have not received thoracic or&#xD;
             mantle irradiation. For patients who have received thoracic or mantle irradiation,&#xD;
             FEV1 and FVC &lt;70% predicted or DLCO &lt; 50 of predicted.&#xD;
&#xD;
          -  Poor liver function: bilirubin &gt;2 mg/dl (not due to hemolysis, Gilbert's or primary&#xD;
             malignancy). ALT or AST &gt; 5 x laboratory upper normal limits.&#xD;
&#xD;
          -  Poor renal function: Creatinine &gt;2.0mg/dl or creatinine clearance (calculated&#xD;
             creatinine clearance is permitted) &lt; 60 mL/min based on Traditional Cockcroft-Gault&#xD;
             formula&#xD;
&#xD;
          -  Women of childbearing potential who currently are pregnant (Î’-HCG+) or who are not&#xD;
             practicing adequate contraception.&#xD;
&#xD;
          -  Uncontrolled viral, bacterial, or fungal infections. Patients with symptoms consistent&#xD;
             with RSV, influenza A, B, or parainfluenza at the time of enrollment will be assayed&#xD;
             for the above viruses and if positive are not eligible for the trial until they are no&#xD;
             longer symptomatic (patients may have continued assay positivity for a period of time&#xD;
             post resolution of symptoms secondary to the nature of the assay).&#xD;
&#xD;
          -  Uncontrolled CNS involvement by malignancy (patients with prior history of CNS disease&#xD;
             controlled with intrathecal chemotherapy or prior systemic therapy are allowed).&#xD;
&#xD;
          -  Patients who have any debilitating medical or psychiatric illness which would preclude&#xD;
             their giving informed consent or their receiving optimal treatment and follow-up.&#xD;
&#xD;
        Exclusion Criteria - Control Patients (specimen collection, only)&#xD;
&#xD;
          -  Undergoing myeloablative alloHSCT.&#xD;
&#xD;
          -  Non-PTCy GVHD prophylaxis.&#xD;
&#xD;
          -  Non-PBSC transplant (bone marrow stem cell source).&#xD;
&#xD;
          -  Not willing to give longitudinal blood specimens for research use or not willing to&#xD;
             allow access to medical records for non-clinical purposes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noah Merin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadia Mehrnoosh Nassaj</last_name>
    <phone>310-423-7735</phone>
    <email>mehrnoosh.nassaj@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Mehrnoosh Nassaj</last_name>
      <phone>310-423-7735</phone>
      <email>mehrnoosh.nassaj@cshs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Noah Merin</investigator_full_name>
    <investigator_title>Assistant Clinical Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Relapsed/Refractory Lymphoma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>CLL</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Haploidentical Stem Cell Transplantation</keyword>
  <keyword>GVHD</keyword>
  <keyword>Allogeneic Stem Cell Transplantation</keyword>
  <keyword>Natural Killer Cell</keyword>
  <keyword>CliniMACS</keyword>
  <keyword>Post-transplantation cyclophosphamide</keyword>
  <keyword>Donor Lymphocyte Infusion</keyword>
  <keyword>Minimal Residual Disease</keyword>
  <keyword>Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

